研究人员发现紫色衍生型环胺可提高质母细胞瘤治疗效果,减少TMZ的使用. Researchers found violet-derived cyclotide enhances glioblastoma treatment efficacy, requiring less TMZ.

怀俄明州脑化学实验室的研究人员发现，源自紫罗兰的环状肽 kalata B1 增强了替莫唑胺 （TMZ） 化疗对胶质母细胞瘤（一种严重的脑癌）的疗效。 Researchers at Brain Chemistry Labs in Wyoming have found that the cyclotide kalata B1, derived from violets, enhances the efficacy of Temozolomide (TMZ) chemotherapy against glioblastoma, a severe brain cancer. kalata B1 的合成版本可以将有效杀死胶质母细胞瘤细胞所需的 TMZ 剂量减少十倍以上。 A synthetic version of kalata B1 can reduce the dosage of TMZ needed to effectively kill glioblastoma cells by over ten-fold. 这一发现可能导致更有效的治疗,尽管仍然需要进一步的测试和临床试验。 This discovery may lead to more effective treatments, although further testing and clinical trials are still needed.